Thomas Moore

After receiving approval for two HIV drugs, Delstrigo and Pifeltro, Merck should be expecting strong sales but probably unlikely to be at blockbuster levels, according to senior pharma analyst at GlobalData. Read more


Following a dip in the first-quarter operating profit announced by Takeda, which is being attributed to the loss of US exclusivity for its blockbuster cancer drug and a lacking pipeline, it may find a saving grace in its recent merger with Shire Read more